- Details
- Cédric Pobel discusses an ancillary study of the PEACE-1 trial, focusing on phenotypic and genomic characterization of de novo metastatic prostate cancer. The study analyzes immunohistochemistry and genomic data from patient biopsies. Key findings include the identification of five phenotypes based on androgen receptor and neuroendocrine marker expression. Notably, about 25% of patients show neuro...
|
- Details
- Michael Hofman discusses the development of new criteria for evaluating prostate cancer progression using PSMA PET-CT scans. This work aims to standardize response evaluation and potentially replace the current PCWG3 guidelines that rely on CT and bone scans. Using data from the PRINCE trial, Dr. Hofman's team demonstrates high inter-reader agreement for the new criteria, with almost perfect agree...
|
- Details
- Oliver Sartor discusses the SPLASH trial results, evaluating Lutetium-177-PNT2002 in metastatic castration-resistant prostate cancer patients who progressed on ARPI therapy. The study shows significant improvement in radiographic progression-free survival for Lutetium-177-PNT2002 compared to alternate ARPI therapy, with a hazard ratio of 0.71. Dr. Sartor highlights the favorable safety profile and...
|
- Details
- Rashid Sayyid and Zachary Klaassen discuss the 2024 NCCN prostate cancer guideline updates for systemic therapy in metastatic hormone-sensitive prostate cancer (mHSPC). They highlight the new stratification of treatment recommendations based on disease volume and timing of metastases. The discussion covers recent clinical trials supporting triplet therapy for high-volume synchronous disease, inclu...
|
- Details
- Daniel Joyce discusses the financial impact of advanced prostate cancer treatments on patients. He presents research showing significant out-of-pocket costs for oral cancer therapies, particularly for commercially insured patients. Dr. Joyce highlights disparities in costs based on factors like age, race, and income. He emphasizes the importance of addressing financial toxicity in patient care, no...
|
- Details
- Piet Ost discusses the STORM trial, a randomized study comparing stereotactic body radiotherapy (SBRT) with elective nodal radiotherapy (ENRT) in oligometastatic prostate cancer patients. The trial, involving 80% PSMA-PET scanned patients, includes six months of androgen deprivation therapy in both arms. Results show significant benefits for ENRT in biochemical recurrence-free survival and locoreg...
|
- Details
- Rashid Sayyid and Zach Klaassen discuss a meta-analysis published in JAMA Oncology examining cardiovascular events associated with androgen receptor signaling inhibitors (ARSIs) in advanced prostate cancer. The study analyzes 24 randomized controlled trials across various prostate cancer stages, involving 22,166 patients. Results show a significant increase in both all-grade and grade 3+ cardiovas...
|
- Details
- Giulia Marvaso discusses the RADIOSA trial, a phase II randomized study comparing SBRT alone versus SBRT with short-course hormonal therapy for oligorecurrent prostate cancer. The trial includes 102 patients with up to three metastatic lesions, randomized into two arms. Results show improved biochemical and clinical progression-free survival in the combination arm. Dr. Marvaso highlights that pati...
|
- Details
- John Babich discusses the potential of radiopharmaceuticals in cancer treatment. He emphasizes the importance of targeting and retention in tumor tissues, explaining the concept of therapeutic index and the company's "radioligand first, isotope second" approach. Dr. Babich highlights their work on FAP (fibroblast activation protein) and their Trillium technology, which aims to optimize drug delive...
|
- Details
- David Crawford discusses with Daniel Petrylak a new approach to treating advanced prostate cancer using a PROTAC agent called ARV-766. Dr. Petrylak explains that PROTACs accelerate the body's natural protein disposal process, targeting the androgen receptor. The phase I/II study of ARV-766 shows promising results in patients with ligand-binding domain mutations, which occur in about 25% of cases....
|
